secwatch.observer — SEC 8-K summary
======================================

Issuer:     TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK:        0000818686
Form:       8-K
Filed at:   2022-02-09T23:59:59+00:00
Accession:  0001157523-22-000164
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Teva reports FY 2021 revenue down 5% to $15.9B; GAAP EPS $0.38; Q4 GAAP loss
----------------------------------------------------------------------------

- FY 2021 revenues $15.9B, down 5% YoY; GAAP diluted EPS $0.38 vs -$3.64 in 2020.
- Q4 2021 GAAP diluted EPS $(0.14); Non-GAAP diluted EPS $0.77.
- FY 2021 non-GAAP diluted EPS $2.58 (flat YoY); free cash flow $2.2B.
- 2022 outlook: revenue $15.6-$16.2B, non-GAAP EPS $2.40-$2.60, FCF $1.9-$2.2B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818686/000115752322000164/0001157523-22-000164-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818686/000115752322000164/a52576299.htm
  HTML page:      https://secwatch.observer/filing/0001157523-22-000164

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer